Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

Phase III trial highlights benefits of intensity modulated proton therapy for oropharyngeal cancer

According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton

June 6, 2024

New insights into how cells generate microRNAs

It’s a big year for microRNAs. The 2024 Nobel Prize in Physiology or Medicine went to Victor Ambros and Gary Ruvkun, who discovered the first

December 2, 2024

Sandoz targets barriers to biosimilar accessibility with latest initiative – Pharmaceutical Technology

The company’s plan has focused on the Americas, but will expand globally over the next year. Source: Shutterstock / OleksSH. Generic and biosimilar pharmaceutical company

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.